Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shockwave with or without DPP-4 inhibitor and teriparatide in ischemic cardiomyopathy
2013-004333-33Phase 2Unknown
- Sponsor
- Imperial College London
- Start
- Dec 2013
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sitagliptin, linagliptin and teriparatide in ischaemic cardiomyopathy (ICM) and heart failure with reduced ejection fraction (HFrEF) (3 arms), sponsored by Imperial College London. Status: unknown.
02
Drugs
sitagliptinlinagliptinteriparatide
03
Conditions
ischaemic cardiomyopathy (ICM)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2013-004333-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004333-33.